• Faculty of Clinical Research (FCR)
  • Global accredited training & certification provider cleanindia
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India.
  • ApprovedTraining Partner of Food Safety and Standards Authority of India (FSSAI)
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Govt. of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017
  • Trusted by organizations & training participants in over 30 countries
    Training | Certification | Education | Research

Honourable Dr. G. N. Singh, Drug Controller General of India presented a Momento by our Director Mr. Syed S. Abbas & Principal Advisor Mr. Vinod Arora on the launch of our Computer System Validation (CSV) programme

IGMPI is conferred with ASSOCHAM Services Excellence Award 2017: Our Directors Mr Syed S. Abbas & Mrs Rafat Abedi, Chief Advisor Dr Mahesh Gupta, Advisor Mr Amitabh Srivastava are being honoured by the Chief Guest & Honorable Member of Parliament Dr. Udit Raj


New partnership towards Parkinson’s disease Research

New partnership towards Parkinson’s disease Research

A new partnership is in pipeline between the National Institutes of Health (NIH), government, biopharmaceutical, life science and non-profit organizations to facilitate advance and promising treatments for Parkinson’s disease (PD). Part of the NIH Accelerating Medicines Partnership (AMP), AMP PD will focus on recognising and validating new biomarkers that may be useful in tracking the progression of PD and could serve as biological targets for the development of new drugs.

Major shortcomings of current treatment option for PD are-

  • Insufficient understanding of biological networks
  • Drugs aimed at seemingly promising therapeutic targets fail in clinical trials

NIH strives to combine expertise and resources AMP PD partners and hope to increase collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.
Parkinson’s disease is a chronic and progressive neurological disorder that largely affects movement and balance, although a subset of people with PD also exhibit cognitive deficits. Due to increased life expectancies worldwide, the number of people with PD is expected to nearly double by the year 2030, which will lead to a significant increase in health care costs. Despite considerable ongoing translational and clinical research efforts, no disease-modifying drugs have yet been approved for PD.
AMP PD partners include Celgene, Summit, New Jersey; GlaxoSmithKline, Philadelphia; The Michael J. Fox Foundation for Parkinson’s Research (MJFF), New York; Pfizer, New York; Sanofi, Bridgewater, New Jersey; and Verily, South San Francisco, California. (See what the partner organizations are saying about AMP PD). All the organizations are expected to pool in total of $ 12 million over the period of 5 years through the Foundation for the National Institutes of Health (FNIH), which will manage the project.

These studies will benefit the AMP PD Knowledge Portal by providing advance knowledge to cater to patients and medical fraternity involved in PD patient care. The partners will analyze combined datasets from more than 3,000 PD cases and 1,700 healthy controls from studies funded by NINDS and MJFF, including the Parkinson’s Progression Markers Initiative. The main focus of the research is to determine which biomarkers show the most potential for predicting disease progression and prognosis. Observations from these from these analyses will be shared via the Knowledge Portal, which will cater to larger audience and provide the opportunity to conduct genome-wide analyses on a large scale.